Home › Companies › NRSN

NeuroSense Therapeutics

NRSN Rare disease Lead: Phase 3 ★ Read the deep dive → 2 Biotech Distilled articles ↓

Neurology Small Molecule

Most recent annual filing: 2026-03-31

Pipeline (3 active programs)

PrimeC

ciprofloxacin · celecoxib · NST003

Amyotrophic Lateral Sclerosis Phase 3 oral

PrimeC

ciprofloxacin · celecoxib

Alzheimer's Disease Phase 2 oral NeuroKaire

StabiliC

ciprofloxacin · celecoxib

Parkinson's Disease Preclinical oral

Biotech Distilled coverage (2)

Articles open on Substack. Some deep dives are subscriber-only.